No description available.

Many cancerous solid tumors metastasize to the bone and induce pain (cancer-induced bone pain [CIBP]). Cancer-induced bone pain is often severe because of enhanced inflammation, rapid bone degradation, and disease progression. Opioids are prescribed to manage this pain, but they may enhance bone loss and increase tumor proliferation, further compromising patient quality of life. Angiotensin-(1-7) (Ang-(1-7)) binds and activates the Mas receptor (MasR). Angiotensin-(1-7)/MasR activation modulates inflammatory signaling after acute tissue insult, yet no studies have investigated whether Ang-(1-7)/MasR play a role in CIBP. We hypothesized that Ang-(1-7) inhibits CIBP by targeting MasR in a murine model of breast CIBP. 66.1 breast cancer cells were implanted into the femur of BALB/cAnNHsd mice as a model of CIBP. Spontaneous and evoked pain behaviors were assessed before and after acute and chronic administration of Ang-(1-7). Tissues were collected from animals for ex vivo analyses of MasR expression, tumor burden, and bone integrity. Cancer inoculation increased spontaneous pain behaviors by day 7 that were significantly reduced after a single injection of Ang-(1-7) and after sustained administration. Preadministration of A-779 a selective MasR antagonist prevented this reduction, whereas pretreatment with the AT(2) antagonist had no effect; an AT(1) antagonist enhanced the antinociceptive activity of Ang-(1-7) in CIBP. Repeated Ang-(1-7) administration did not significantly change tumor burden or bone remodeling. Data here suggest that Ang-(1-7)/MasR activation significantly attenuates CIBP, while lacking many side effects seen with opioids. Thus, Ang-(1-7) may be an alternative therapeutic strategy for the nearly 90% of patients with advanced-stage cancer who experience excruciating pain.

Angiotensin-(1-7) [Ang-(1-7)] is a heptapeptide component of the renin angiotensin system and the endogenous ligand for the Mas receptor. Ang-(1-7) is generated mainly via angiotensin converting enzyme 2 (ACE2)-dependent cleavage of Angiotensin (Ang) II. Studies suggest Ang-(1-7) may protect against progression of renal injury in experimental models of chronic kidney disease, although the responses may be dose dependent. The role of Ang-(1-7) in the progression of renal fibrosis in unilateral ureteral obstruction (UUO) remains unclear. We tested the hypothesis that endogenous Ang-(1-7) and low dose exogenous Ang-(1-7) would protect against renal injury in the UUO model, while high dose Ang-(1-7) would exacerbate renal injury. Male C57Bl/6 mice underwent UUO and received vehicle, the Ang-(1-7) antagonist A779, or one of three doses of Ang-(1-7) for 10 days. Treatment with A779 exacerbated renal injury as seen by increased fibronectin, transforming growth factor-β (TGF-β), and α-smooth muscle actin (α-SMA) expression, increased tubulointerstitial fibrosis scores, macrophage infiltration, apoptosis, and NADPH oxidase activity in obstructed kidneys. Paradoxically, delivery of exogenous Ang-(1-7) was associated with increased renal injury regardless of dose. Taken together, these data indicate the Mas receptor may be sensitive to concentrations of Ang-(1-7) within the obstructed kidney and that exogenous Ang-(1-7) stimulates pro-fibrotic and pro-inflammatory signalling through unclear pathways.

Angiotensin-(1-7) [Ang-(1-7)] is a heptapeptide component of the renin angiotensin system and the endogenous ligand for the Mas receptor. Ang-(1-7) is generated mainly via angiotensin converting enzyme 2 (ACE2)-dependent cleavage of Angiotensin (Ang) II. Studies suggest Ang-(1-7) may protect against progression of renal injury in experimental models of chronic kidney disease, although the responses may be dose dependent. The role of Ang-(1-7) in the progression of renal fibrosis in unilateral ureteral obstruction (UUO) remains unclear. We tested the hypothesis that endogenous Ang-(1-7) and low dose exogenous Ang-(1-7) would protect against renal injury in the UUO model, while high dose Ang-(1-7) would exacerbate renal injury. Male C57Bl/6 mice underwent UUO and received vehicle, the Ang-(1-7) antagonist A779, or one of three doses of Ang-(1-7) for 10 days. Treatment with A779 exacerbated renal injury as seen by increased fibronectin, transforming growth factor-β (TGF-β), and α-smooth muscle actin (α-SMA) expression, increased tubulointerstitial fibrosis scores, macrophage infiltration, apoptosis, and NADPH oxidase activity in obstructed kidneys. Paradoxically, delivery of exogenous Ang-(1-7) was associated with increased renal injury regardless of dose. Taken together, these data indicate the Mas receptor may be sensitive to concentrations of Ang-(1-7) within the obstructed kidney and that exogenous Ang-(1-7) stimulates pro-fibrotic and pro-inflammatory signalling through unclear pathways.

Angiotensin-(1-7) [Ang-(1-7)] is a heptapeptide component of the renin angiotensin system and the endogenous ligand for the Mas receptor. Ang-(1-7) is generated mainly via angiotensin converting enzyme 2 (ACE2)-dependent cleavage of Angiotensin (Ang) II. Studies suggest Ang-(1-7) may protect against progression of renal injury in experimental models of chronic kidney disease, although the responses may be dose dependent. The role of Ang-(1-7) in the progression of renal fibrosis in unilateral ureteral obstruction (UUO) remains unclear. We tested the hypothesis that endogenous Ang-(1-7) and low dose exogenous Ang-(1-7) would protect against renal injury in the UUO model, while high dose Ang-(1-7) would exacerbate renal injury. Male C57Bl/6 mice underwent UUO and received vehicle, the Ang-(1-7) antagonist A779, or one of three doses of Ang-(1-7) for 10 days. Treatment with A779 exacerbated renal injury as seen by increased fibronectin, transforming growth factor-β (TGF-β), and α-smooth muscle actin (α-SMA) expression, increased tubulointerstitial fibrosis scores, macrophage infiltration, apoptosis, and NADPH oxidase activity in obstructed kidneys. Paradoxically, delivery of exogenous Ang-(1-7) was associated with increased renal injury regardless of dose. Taken together, these data indicate the Mas receptor may be sensitive to concentrations of Ang-(1-7) within the obstructed kidney and that exogenous Ang-(1-7) stimulates pro-fibrotic and pro-inflammatory signalling through unclear pathways.

Angiotensin-(1-7) (Ang-(1-7)) is reported to be equipotent with angiotensin II (AII) in producing some central biological effects but the receptors responsible for these actions have not been defined. Three classes of receptor have been proposed: AT1, AT2, and a putative Ang-(1-7) selective receptor. This study specifically evaluates Ang-(1-7) competition at AII binding sites (AT1 and AT2) in the rat brain. 125I Sar1 Ile8 AII (269-312 pM) was used to conduct receptor autoradiographic binding assays in brain sections. Competition with Ile5 AII and Val5 AII was similar at nuclei in which either AT1 or AT2 receptor subtypes predominate (Ki = 11-18 nM). Ang-(1-7) competed 150-fold less effectively than native AII at AT1 predominant brain nuclei (Ki = 2.4 μM). At brain regions where AT2 receptors predominate, Ang-(1-7) showed a very low affinity (Ki = 104 μM) for the majority of the 125I Sar1 Ile8 AII binding sites (AT2). A small proportion of 125I Sar1 Ile3 AII binding sites showed an affinity of 2.0 μM, presumably AT1 receptors present in those brain regions. For biological responses where Ang-(1-7) is reported to be equipotent with AII, it is unlikely that these actions are mediated by the widely distributed AT1 or AT2 receptor subtypes which recognize 125I Sar1 Ile8 AII.

Aim: Obesity is a risk factor for the development of cardiovascular diseases. Recently it was shown that overexpression of the Mas-receptor antagonist angiotensin(1-7) could prevent from diet-induced obesity. However, it remained unclear whether diet-induced obesity and angiotensin(1-7) overexpression might also have effects on the cardiovascular system in these rats. Methods:Twenty three male Sprague Dawley rats were fed with standard chow (SD+chow, n = 5) or a cafeteria diet (SD+CD, n = 6) for 5 months. To investigate the effect of angiotensin(1-7) transgenic rats, expressing an angiotensin(1-7)-producing fusion protein in testis were used. These transgenic rats also received a 5 month's feeding period with either chow (TGR+chow, n = 6) or cafeteria diet (TGR+CD, n = 6), respectively. Hemodynamic measurements (pressure-volume loops) were carried out to assess cardiac function and blood pressure. Subsequently, hearts were explanted and investigated according to the Langendorff technique. Furthermore, cardiac remodeling in these animals was investigated histologically. Results:After 5 months cafeteria diet feeding rats showed a significantly increased body weight, which could be prevented in transgenic rats. However, there was no effect on cardiac performance after cafeteria diet in non-transgenic and transgenic rats. Moreover, overexpression of angiotensin(1-7) deteriorated cardiac contractility as indicated by impaired dp/dt. Furthermore, histological analysis revealed that cafeteria diet led to myocardial fibrosis in both, control and transgenic rats and this was not inhibited by an overproduction of angiotensin(1-7). Conclusion:These results indicate that an overexpression of circulating angiotensin(1-7) prevents a cafeteria diet-induced increase in body weight, but does not affect cardiac performance in this experimental rat model of obesity. Furthermore, overexpression of angiotensin(1-7) alone resulted in an impairment of cardiac function.

Obesity is strongly associated with hypertension and cardiovascular diseases. An activated renin-angiotensin system (RAS) has long been suggested as a critical contributor to elevated blood pressure with obesity. Angiotensin II (AngII), the main effector of an activated RAS, can be catabolized by angiotensin-converting enzyme 2 (ACE2) to form angiotensin-(1-7) (Ang-(1-7)), which, acting through the mas receptor (MasR), has been shown to oppose the effects of an activated RAS. Therefore, further understanding of the mechanisms of this counter-regulatory arm, called the ACE2/Ang-(1-7)/MasR axis, may lead to new therapies for obesity-induced hypertension. Previously, we demonstrated that differences in the regulation of ACE2 in a tissue-specific manner contribute to sexual dimorphism of diet-induced obesity-hypertension in mice. Whereas male mice fed a high fat (HF) diet developed hypertension, HF-fed female mice were protected from obesity-hypertension, and this was associated with increased activity of ACE2 in adipose tissue of females. Both upregulation of adipose ACE2 and protection against obesity-hypertension were lost when females were ovariectomized (OVX). We hypothesized that estrogen-mediated increases in adipose ACE2 reduce the AngII/Ang-(1-7) peptide balance and protect females from obesity-hypertension. To test this hypothesis, we first determined if estrogen restores protection of Ovx female mice from obesity-hypertension, and therapeutically protects male mice from obesity-hypertension. We demonstrated that estrogen administration to Ovx HF-fed females activates adipose ACE2, reduces plasma Ang II concentrations, and decreases blood pressure in wildtype, but not of ACE2-deficient obese females. In contrast, estrogen administration to HF-fed male mice had no on the development of obesity-hypertension, regardless of genotype. These results demonstrate that estrogen protects female mice from obesity-hypertension through an ACE2-dependent mechanism. Next we defined the role of MasR deficiency on the development of obesity-hypertension in male and female mice. In HF-fed MasR-deficient female mice, diastolic blood pressure (DBP) was significantly elevated compared to LF-fed controls, suggesting that protection from obesity-hypertension was abolished by MasR deficiency. In contrast, HF-fed male mice with MasR deficiency exhibited reduced blood pressure compared to wildtype controls which was associated with reduced cardiac function. Overall, these studies indicate that the ACE2/Ang-(1-7)/MasR axis plays an important role in sexual dimorphism of obesity-hypertension, and in the regulation of cardiac function. Moreover, these studies suggest that the effects of this counter-regulatory arm of the RAS may be sex-specific.

Interação entre angiotensina-(1-7) [Ang-(1-7)] e bradicinina (BK) foi determinada no mesentério de ratos Wistar anestesiados utilizando-se microscopia intravital. Aplicação tópica de BK e Ang-(1-7) induziram vasodilatação que foi abolida por HOE-140 e A-779, respectivamente. Ang-(1-7) (100 pmol) potencializou a vasodilatação de BK (1 pmol) mas não a vasodilatação promovida por acetilcolina, nitroprussiato de sódio, histamina e ácido araquidônico. O efeito potencializador de Ang-(1-7) sobre BK foi abolido por A-779, HOE-140, indometacina, L-NAME e TEA, entretanto, losartan não bloqueou este efeito. Enalaprilato aumentou a resposta vasodilatadora de BK e Ang-(1-7) e não alterou o efeito potencializador do segundo sobre o primeiro. Conclui-se que: 1)efeito potencializador de Ang-(1-7) sobre BK depende da interação de ambos com seus respectivos receptores; 2)é dependente de óxido nítrico, produtos da cicloxigenase e hiperpolarização de membrana via canais de potássio; 3) o mecanismo de potencialização parece não depender da atividade catalítica da ECA. / The interaction between angiotensin-(1-7) [Ang-(1-7)] and bradykinin (BK) was determined in the mesentery of anesthetized Wistar rats using intravital microscopy. The response-induced by topical application of BK (1, 10 and 30 pmol), Ang-(1-7) (1, 10, 100 and 1000 pmol) and Ang-(1-7) (100 pmol) + BK (1 pmol) was determined in mesenteric arterioles (15-20 mm diameter). The BK (1 pmol)- and Ang-(1-7) (100 pmol)- induced vasodilation was abolished by BK B2 receptor antagonist HOE-140 (100 pmol applied during 60 seconds) and the Ang-(1-7) antagonist [d-Ala7]-Ang-(1-7)] (A-779) (100 pmol applied during 15 seconds), respectively. Indomethacin (5 mg/kg; IM, 30 min before), a cyclooxygenase inhibitor; L-NAME (10 nmol; topical application, 3 min before), a NO synthase inhibitor, decreased the Ang-(1-7)-induced vasodilation. However, TEA (90 pmol; topical application), a non specific K+ channels blocker, did not alter the response to BK or Ang-(1-7). BK (1 pmol)-induced vasodilation, however, was potentiated by Ang-(1-7) 100 pmol. Sodium nitroprusside (38 pmol), acetylcholine (1,6 nmol), histamine (5,4 nmol) and arachdonic acid (10 nmol) responses were not modified by Ang-(1-7) 100 pmol. The Ang-(1-7)-potentiating effect on BK-induced vasodilation was abolished by A-779, HOE-140, indomethacin, L-NAME and TEA. Losartan (15 mg/kg.IV, 40 min before), an AT1 angiotensin receptor antagonist was without effect. On the other hand, enalaprilat treatment (10 mg/kg; IV, 30 min before), to inhibit angiotensin-converting enzyme (ACE), enhanced the BK and Ang-(1-7)-induced vasodilation but did not modify the effect of Ang-(1-7) on BK vasodilation. In conclusion, the potentiation of BK-induced vasodilation by Ang-(1-7) is a receptor-mediated phenomenon dependent on cyclooxygenase-related products, NO release and K+ channel-mediated membrane hyperpolarization. The potentiating mechanism, apparently, is not related to ACE catalytic activity.

A ação aguda direta da Ang-(1-7) sobre o fluxo reabsortivo de bicarbonato (JHCO3-) foi avaliada por microperfusão estacionária in vivo em túbulos proximais de ratos utilizando microelétrodo sensível a H+. Em ratos WKY, a Ang-(1-7) tem efeito bifásico sobre o NHE3: em baixas concentrações causa queda do JHCO3-, enquanto que em altas concentrações estimula o JHCO3-. Em ratos SHR, a Ang-(1-7) demonstrou efeitos opostos aos dos ratos WKY; a Ang-(1-7; 10-9 M) aumentou o JHCO3-, enquanto a Ang (1-7; 10-6 M) causou significante queda do JHCO3-. Em adição, monitoramos fluorimétricamente a concentração de cálcio citosólico ([Ca2+]i) em túbulos proximais isolados, por meio do probe sensivél a cálcio FURA-2-AM. Nossos dados indicam que a [Ca2+]i em ratos WKY no controle é 99,7 ± 2,28 nM; a Ang-(1-7) aumenta esse valor. Em animais SHR o controle é 94,3 ± 1,66 nM; a Ang-(1-7) aumenta esse valor. Em conclusão, nossos dados indicam que a interação dos efeitos opostos dose dependente da Ang-(1-7) e Ang II sobre JHCO3- e a [Ca2+]i representa importante mecanismo de regulação fisiológica do volume e do pH intra-extracelular. / Direct acute effects of Ang-(1-7) on the resorptive bicarbonate flow (JHCO3-) was evaluated by stationary microperfusion in vivo in proximal tubules using microelectrode sensitive to H+. In WKY control rats, Ang-(1-7) has biphasic effects on Na+/H+ exchanger isoform 3 (NHE3): at low dose inhibits and at higher one stimulates the NHE3. In SHR rats, Ang-(1-7) displayed opposite effects on SHR when compared to WKY rats: Ang- (1-7) at low dose increases JHCO3- whereas Ang (1-7) at higher dose reduces JHCO3-. In addition, we have fluorimetrically monitored cytosolic calcium ([Ca2+]i) in isolated proximal tubule through FURA-2-AM. Our data show that [Ca2+]i in the WKY control group is 99.7 ± 2.28 nM. Ang-(1-7) at 10-9 or 10-6 M increases [Ca2+]i. In SHR control rats [Ca2+]i is 94.3 ± 1.66 nM; Ang-(1-7) increase [Ca2+]i. Thus, our data are indicating that the interaction of the opposing dose-dependent effects of Ang-(1-7) and Ang II on JHCO3- and [Ca2+]i may represent an important physiological mechanism for regulating the intra and extracellular volume and pH in normotensive and hypertensive individuals.